The functional performance of the Argus II retinal prosthesis

H. Christiaan Stronks, Gislin Dagnelie

Research output: Contribution to journalArticle

Abstract

Visual prostheses are devices to treat profound vision loss by stimulating nerve cells anywhere along the visual pathway, typically with electrical pulses. The Argus® II implant, developed by Second Sight Medical Products (SSMP, Sylmar, CA, USA), targets the retina and features 60 electrodes that electrically stimulate the surviving retinal neurons. Of the approximately 20 research groups that are actively developing visual prostheses, SSMP has the longest track record. The Argus II was the first visual prosthesis to become commercially available: it received the European conformity mark in 2011 and FDA approval was granted in early 2013 for humanitarian use in the USA. Meanwhile, the Argus II safety/benefit study has been extended for research purposes, and is still ongoing. In this review, we will discuss the performance of the Argus II in restoring sight to the blind, and we will shed light on its expected developments in the coming years.

Original languageEnglish (US)
Pages (from-to)23-30
Number of pages8
JournalExpert Review of Medical Devices
Volume11
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Visual Prosthesis
Prosthetics
Neurons
Retinal Neurons
Visual Pathways
Research
Electrodes
Retina
Safety
Equipment and Supplies
Prostheses and Implants

Keywords

  • Argus II
  • electrical stimulation of the retina
  • epiretinal implant
  • low vision
  • retinal prosthesis
  • retinitis pigmentosa
  • spatial resolution
  • vision rehabilitation
  • visual acuity
  • visual prosthetics

ASJC Scopus subject areas

  • Surgery
  • Biomedical Engineering

Cite this

The functional performance of the Argus II retinal prosthesis. / Stronks, H. Christiaan; Dagnelie, Gislin.

In: Expert Review of Medical Devices, Vol. 11, No. 1, 01.2014, p. 23-30.

Research output: Contribution to journalArticle

@article{a0143be1b5b04f8699c7bf3a91a2709d,
title = "The functional performance of the Argus II retinal prosthesis",
abstract = "Visual prostheses are devices to treat profound vision loss by stimulating nerve cells anywhere along the visual pathway, typically with electrical pulses. The Argus{\circledR} II implant, developed by Second Sight Medical Products (SSMP, Sylmar, CA, USA), targets the retina and features 60 electrodes that electrically stimulate the surviving retinal neurons. Of the approximately 20 research groups that are actively developing visual prostheses, SSMP has the longest track record. The Argus II was the first visual prosthesis to become commercially available: it received the European conformity mark in 2011 and FDA approval was granted in early 2013 for humanitarian use in the USA. Meanwhile, the Argus II safety/benefit study has been extended for research purposes, and is still ongoing. In this review, we will discuss the performance of the Argus II in restoring sight to the blind, and we will shed light on its expected developments in the coming years.",
keywords = "Argus II, electrical stimulation of the retina, epiretinal implant, low vision, retinal prosthesis, retinitis pigmentosa, spatial resolution, vision rehabilitation, visual acuity, visual prosthetics",
author = "Stronks, {H. Christiaan} and Gislin Dagnelie",
year = "2014",
month = "1",
doi = "10.1586/17434440.2014.862494",
language = "English (US)",
volume = "11",
pages = "23--30",
journal = "Expert Review of Medical Devices",
issn = "1743-4440",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - The functional performance of the Argus II retinal prosthesis

AU - Stronks, H. Christiaan

AU - Dagnelie, Gislin

PY - 2014/1

Y1 - 2014/1

N2 - Visual prostheses are devices to treat profound vision loss by stimulating nerve cells anywhere along the visual pathway, typically with electrical pulses. The Argus® II implant, developed by Second Sight Medical Products (SSMP, Sylmar, CA, USA), targets the retina and features 60 electrodes that electrically stimulate the surviving retinal neurons. Of the approximately 20 research groups that are actively developing visual prostheses, SSMP has the longest track record. The Argus II was the first visual prosthesis to become commercially available: it received the European conformity mark in 2011 and FDA approval was granted in early 2013 for humanitarian use in the USA. Meanwhile, the Argus II safety/benefit study has been extended for research purposes, and is still ongoing. In this review, we will discuss the performance of the Argus II in restoring sight to the blind, and we will shed light on its expected developments in the coming years.

AB - Visual prostheses are devices to treat profound vision loss by stimulating nerve cells anywhere along the visual pathway, typically with electrical pulses. The Argus® II implant, developed by Second Sight Medical Products (SSMP, Sylmar, CA, USA), targets the retina and features 60 electrodes that electrically stimulate the surviving retinal neurons. Of the approximately 20 research groups that are actively developing visual prostheses, SSMP has the longest track record. The Argus II was the first visual prosthesis to become commercially available: it received the European conformity mark in 2011 and FDA approval was granted in early 2013 for humanitarian use in the USA. Meanwhile, the Argus II safety/benefit study has been extended for research purposes, and is still ongoing. In this review, we will discuss the performance of the Argus II in restoring sight to the blind, and we will shed light on its expected developments in the coming years.

KW - Argus II

KW - electrical stimulation of the retina

KW - epiretinal implant

KW - low vision

KW - retinal prosthesis

KW - retinitis pigmentosa

KW - spatial resolution

KW - vision rehabilitation

KW - visual acuity

KW - visual prosthetics

UR - http://www.scopus.com/inward/record.url?scp=84893037341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893037341&partnerID=8YFLogxK

U2 - 10.1586/17434440.2014.862494

DO - 10.1586/17434440.2014.862494

M3 - Article

VL - 11

SP - 23

EP - 30

JO - Expert Review of Medical Devices

JF - Expert Review of Medical Devices

SN - 1743-4440

IS - 1

ER -